Advertisement

Lymphoma Medications

Here's a list of the approved drugs to treat lyphoma, including non-Hodgkin and Hodgkin lymphoma. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG RECOMMENDATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, liver cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Kymriah
GENERIC NAME tisagenlecleucel
DRUG RECOMMENDATION

Kymriah is a CAR-T therapy approved for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults up to age 25 and for relapsed or refractory diffuse large B-cell lymphoma in adults.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG RECOMMENDATION

Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Revlimid
GENERIC NAME lenalidomide
DRUG RECOMMENDATION

Revlimid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone, and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Yescarta
GENERIC NAME axicabtagene ciloleucel
DRUG RECOMMENDATION

Yescarta is a CAR-T therapy approved for relapsed or refractory large B-cell lymphoma (type of non-Hodgkin lymphoma) in adults, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma.

DRUG Adcetris
GENERIC NAME brentuximab vedotin
DRUG RECOMMENDATION

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma, classical Hodgkin lymphoma and peripheral T-cell lymphoma.

 

DRUG Aliqopa
GENERIC NAME copanlisib
DRUG RECOMMENDATION

Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.

DRUG Arranon
GENERIC NAME nelarabine
DRUG RECOMMENDATION

Arranon is a nucleoside inhibitor approved for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that does not respond to chemotherapy.

DRUG Arzerra
GENERIC NAME ofatumumab
DRUG RECOMMENDATION

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

DRUG Beleodaq
GENERIC NAME belinostat
DRUG RECOMMENDATION

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

DRUG Calquence
GENERIC NAME acalabrutinib
DRUG RECOMMENDATION

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma.

DRUG Copiktra
GENERIC NAME duvelisib
DRUG RECOMMENDATION

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

DRUG Gazyva
GENERIC NAME obinutuzumab
DRUG RECOMMENDATION

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

DRUG Imbruvica
GENERIC NAME ibrutinib
DRUG RECOMMENDATION

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia.

DRUG Istodax
GENERIC NAME romidepsin
DRUG RECOMMENDATION

Istodax is an HDAC inhibitor approved for previously treated cutaneous and peripheral T-cell lymphoma.

DRUG Rituxan
GENERIC NAME rituxumab
DRUG RECOMMENDATION

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima is a biosimilar medication.

DRUG Velcade
GENERIC NAME bortezomib
DRUG RECOMMENDATION

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

DRUG Zolinza
GENERIC NAME vorinostat
DRUG RECOMMENDATION

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

 

DRUG Zydelig
GENERIC NAME idelalisib
DRUG RECOMMENDATION

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

Advertisement

Hot topics